Insulin resistance in muscle, liver and ß-cell represent the core pathophysiologic defects in type 2 diabetes. In addition, the ominous octet all play important roles in the development of glucose intolerance in people with type 2 diabetes. How will this new paradigm shift our understanding in the way we treat our type 2 patients? Dr. Ralph DeFronzo, professor of medicine and author of the recent Banting Lecture, “From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus,” discusses new therapies based on the pathophysiology. Join host Dr. Steven Edelman to learn more.
A New Paradigm for the Treatment of Type 2 Diabetes
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Insulin resistance in muscle, liver and ß-cell represent the core pathophysiologic defects in type 2 diabetes. In addition, the ominous octet all play important roles in the development of glucose intolerance in people with type 2 diabetes. How will this new paradigm shift our understanding in the way we treat our type 2 patients? Dr. Ralph DeFronzo, professor of medicine and author of the recent Banting Lecture, “From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus,” discusses new therapies based on the pathophysiology. Join host Dr. Steven Edelman to learn more.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Digesting IgG4-RD: An Interactive, Multidisciplinary Case Conference
Episode 2 Part B: Effectively Transferring Over the CKD Patient at the Right Time
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Level Up Your Skills: Tailoring Management of HF
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?